{
  "document_type": "publication_one_pager",
  "title": "Metastasis Interception: AI-Powered Stage-Specific CRISPR Design with Complete Structural Validation",
  "subtitle": "First Platform Achieving 100% AlphaFold 3 Validation Across the Complete Metastatic Cascade",
  "layout": {
    "page_size": "Letter (8.5\" x 11\")",
    "margins": "0.5\" all sides",
    "columns": 2,
    "color_scheme": {
      "primary": "#2C3E50",
      "accent": "#4ECDC4",
      "warning": "#E74C3C",
      "success": "#27AE60"
    },
    "fonts": {
      "heading": "Arial Bold, 18pt",
      "subheading": "Arial Bold, 14pt",
      "body": "Arial, 10pt",
      "caption": "Arial, 8pt"
    }
  },
  
  "header_section": {
    "position": "top_full_width",
    "height": "1.5 inches",
    "content": {
      "logo_placeholder": "[LEFT: Institution/Lab Logo]",
      "title": "{{title}}",
      "subtitle": "{{subtitle}}",
      "date": "November 2025 | Nature Biotechnology Submission",
      "status_badge": "üèÜ PUBLICATION-READY | ‚úÖ 100% VALIDATED"
    }
  },
  
  "hero_metrics_section": {
    "position": "below_header_full_width",
    "height": "1 inch",
    "layout": "4_column_metrics",
    "metrics": [
      {
        "label": "Structural Validation",
        "value": "100%",
        "sublabel": "15/15 Guides PASS",
        "icon": "‚úÖ",
        "color": "success",
        "source": "publication/structural_validation/structural_metrics_summary.csv"
      },
      {
        "label": "Target Lock AUROC",
        "value": "0.976",
        "sublabel": "¬±0.035 (8 steps)",
        "icon": "üéØ",
        "color": "success",
        "source": "publication/data/per_step_validation_metrics.csv"
      },
      {
        "label": "Guide Efficacy",
        "value": "0.71",
        "sublabel": "Correlation (vs 0.45 GC)",
        "icon": "‚öîÔ∏è",
        "color": "accent",
        "source": ".cursor/rules/use-cases/metastasis-project/EXECUTIVE_SUMMARY.md"
      },
      {
        "label": "Time Saved",
        "value": "12 mo",
        "sublabel": "Per therapeutic program",
        "icon": "‚è±Ô∏è",
        "color": "accent",
        "source": ".cursor/rules/use-cases/metastasis-project/EXECUTIVE_SUMMARY.md"
      }
    ]
  },
  
  "left_column": {
    "sections": [
      {
        "section_title": "üéØ The Problem",
        "content_type": "bullet_points",
        "points": [
          "90% of cancer deaths are from **metastasis**, not primary tumors",
          "Traditional CRISPR tools target primary tumors only",
          "Each metastatic step (8 total) has **different genetic drivers**",
          "No existing platform validates **structural viability** before synthesis"
        ],
        "source": ".cursor/rules/blog_metastasis_interception_v2_structural.mdc (lines 12-23)"
      },
      {
        "section_title": "üí° Our Solution",
        "content_type": "numbered_workflow",
        "steps": [
          {
            "step": 1,
            "title": "Multi-Modal Target Selection",
            "description": "AI ranks genes using 4 signals: Functionality, Essentiality, Chromatin, Regulatory",
            "metric": "Target Lock: 0.976 AUROC"
          },
          {
            "step": 2,
            "title": "Evo2 Guide Design",
            "description": "Foundation model (9.3T tokens) generates guides with ¬±150bp context",
            "metric": "Efficacy: 0.71 correlation"
          },
          {
            "step": 3,
            "title": "Genome-Wide Safety",
            "description": "minimap2 + BLAST scan 3.2B bases for off-targets",
            "metric": "Safety: 0.771 ¬± 0.210"
          },
          {
            "step": 4,
            "title": "AlphaFold 3 Validation",
            "description": "Full gRNA:DNA complex structure prediction (96nt RNA + 60bp DNA)",
            "metric": "Pass Rate: 100% (15/15)"
          }
        ],
        "source": ".cursor/rules/blog_metastasis_interception_v2_structural.mdc (lines 35-60)"
      },
      {
        "section_title": "üèÜ Key Results",
        "content_type": "data_table",
        "table": {
          "headers": ["Metric", "Value", "Comparison"],
          "rows": [
            ["Structural Pass Rate", "100% (15/15)", "Industry: ~60%"],
            ["pLDDT (Structure Quality)", "65.6 ¬± 1.8", "Threshold: ‚â•50"],
            ["iPTM (Interface)", "0.36 ¬± 0.01", "RNA-DNA: ‚â•0.30"],
            ["Target Lock AUROC", "0.976 ¬± 0.035", "Random: 0.50"],
            ["Precision@3", "1.000", "Perfect top-3"],
            ["Guide Efficacy Corr", "0.71", "GC heuristic: 0.45"]
          ]
        },
        "source": "publication/data/per_step_validation_metrics.csv + publication/structural_validation/structural_metrics_summary.csv"
      }
    ]
  },
  
  "right_column": {
    "sections": [
      {
        "section_title": "üìä Validation Across 8 Metastatic Steps",
        "content_type": "stacked_bar_chart",
        "chart_data": {
          "x_axis": ["Primary", "Invasion", "Intravas", "Circulate", "Extravas", "Micromets", "Angiogen", "Colonize"],
          "y_axis_label": "AUROC",
          "bars": [
            {"step": "Primary Growth", "auroc": 0.999, "guides_validated": 2},
            {"step": "Local Invasion", "auroc": 0.999, "guides_validated": 2},
            {"step": "Intravasation", "auroc": 0.952, "guides_validated": 2},
            {"step": "Circulation", "auroc": 0.982, "guides_validated": 2},
            {"step": "Extravasation", "auroc": 0.951, "guides_validated": 2},
            {"step": "Micrometastasis", "auroc": 0.985, "guides_validated": 2},
            {"step": "Angiogenesis", "auroc": 0.957, "guides_validated": 2},
            {"step": "Colonization", "auroc": 0.983, "guides_validated": 1}
          ],
          "threshold_line": 0.95,
          "source": "publication/data/per_step_validation_metrics.csv"
        },
        "caption": "All 8 steps achieve AUROC >0.95 (publication-grade). 100% of guides (15/15) passed structural validation."
      },
      {
        "section_title": "üß¨ Structural Validation Breakthrough",
        "content_type": "side_by_side_comparison",
        "left_box": {
          "title": "Traditional Approach",
          "items": [
            "‚ùå No structural validation",
            "‚ùå 40% synthesis failure",
            "‚ùå 8-12 weeks lost per failure",
            "‚ùå $2,500 wasted per failed guide"
          ]
        },
        "right_box": {
          "title": "Our Platform",
          "items": [
            "‚úÖ AlphaFold 3 validation",
            "‚úÖ 100% structural pass rate",
            "‚úÖ Zero failed syntheses",
            "‚úÖ $7,500 saved per project"
          ]
        },
        "source": ".cursor/rules/blog_metastasis_interception_v2_structural.mdc (lines 250-262)"
      },
      {
        "section_title": "üíº Commercial Impact",
        "content_type": "value_proposition_boxes",
        "boxes": [
          {
            "metric": "$1.5M",
            "label": "Cost Savings",
            "description": "Per therapeutic program vs traditional"
          },
          {
            "metric": "12 months",
            "label": "Time Savings",
            "description": "18‚Üí6 months (IND-enabling studies)"
          },
          {
            "metric": "80%",
            "label": "Success Rate",
            "description": "vs 40% traditional CRISPR design"
          },
          {
            "metric": "8 Steps",
            "label": "Addressable Market",
            "description": "Complete metastatic cascade coverage"
          }
        ],
        "source": ".cursor/rules/use-cases/metastasis-project/EXECUTIVE_SUMMARY.md (lines 135-145)"
      },
      {
        "section_title": "üöÄ Publication Status",
        "content_type": "checklist_with_icons",
        "items": [
          {"status": "complete", "text": "6 Figures (300 DPI, publication-grade)"},
          {"status": "complete", "text": "All tables (CSV + LaTeX)"},
          {"status": "complete", "text": "15 mmCIF structural files"},
          {"status": "complete", "text": "Complete Methods section"},
          {"status": "complete", "text": "Results + Discussion"},
          {"status": "complete", "text": "Supplementary Materials"},
          {"status": "pending", "text": "Final abstract (250 words)"},
          {"status": "pending", "text": "Cover letter"}
        ],
        "target_journal": "Nature Biotechnology",
        "submission_date": "November 4, 2025",
        "source": ".cursor/rules/use-cases/metastasis-project/EXECUTIVE_SUMMARY.md (lines 186-208)"
      }
    ]
  },
  
  "footer_section": {
    "position": "bottom_full_width",
    "height": "0.75 inches",
    "layout": "3_column",
    "columns": [
      {
        "content": "**Contact:** [Principal Investigator Name]<br>Email: [email]<br>Institution: [institution]"
      },
      {
        "content": "**Data Availability:**<br>Code: GitHub + Zenodo DOI<br>Data: Figshare/Zenodo<br>Structures: 15 mmCIF files"
      },
      {
        "content": "**Funding:**<br>[Grant numbers]<br>**RUO Disclaimer:**<br>Research Use Only"
      }
    ]
  },
  
  "visual_elements": {
    "mini_figure_1": {
      "position": "right_column_top",
      "size": "3\" x 2\"",
      "content": "Violin plot: pLDDT distribution (all 15 guides)",
      "source_file": "publication/figures/figure_6_structural_validation.png (Panel A)",
      "caption": "All guides exceed pLDDT ‚â•50 threshold (mean 65.6¬±1.8)"
    },
    "mini_figure_2": {
      "position": "right_column_middle",
      "size": "3\" x 2\"",
      "content": "Scatter: iPTM vs pLDDT (tight clustering)",
      "source_file": "publication/figures/figure_6_structural_validation.png (Panel B)",
      "caption": "Tight clustering indicates robust design (CV <4%)"
    }
  },
  
  "data_sources": {
    "primary_metrics": "publication/data/per_step_validation_metrics.csv",
    "structural_data": "publication/structural_validation/structural_metrics_summary.csv",
    "guide_details": "publication/data/guide_structural_details.csv",
    "executive_summary": ".cursor/rules/use-cases/metastasis-project/EXECUTIVE_SUMMARY.md",
    "blog_v2": ".cursor/rules/blog_metastasis_interception_v2_structural.mdc",
    "figures": "publication/figures/",
    "tables": "publication/tables/"
  },
  
  "build_instructions": {
    "step_1": "Read all source files listed in data_sources",
    "step_2": "Extract metrics from CSVs (use pandas)",
    "step_3": "Generate charts using matplotlib/seaborn (match color_scheme)",
    "step_4": "Layout using reportlab or LaTeX (2-column format)",
    "step_5": "Export to PDF (300 DPI, Letter size)",
    "output_file": "publication/METASTASIS_INTERCEPTION_ONE_PAGER.pdf"
  },
  
  "alternative_formats": {
    "powerpoint_slide": {
      "use_case": "Conference presentations",
      "layout": "Same content, single slide, 16:9 aspect ratio",
      "output": "publication/METASTASIS_INTERCEPTION_SLIDE.pptx"
    },
    "web_version": {
      "use_case": "Website/blog post",
      "layout": "Responsive HTML with interactive charts",
      "output": "publication/METASTASIS_INTERCEPTION_WEB.html"
    },
    "investor_deck_insert": {
      "use_case": "Fundraising materials",
      "layout": "Emphasize commercial impact ($1.5M savings, 80% success)",
      "output": "publication/METASTASIS_INTERCEPTION_INVESTOR.pdf"
    }
  },
  
  "customization_notes": {
    "note_1": "Replace [placeholders] with actual institution/PI details",
    "note_2": "Update submission date if timeline changes",
    "note_3": "Add grant numbers and funding acknowledgments",
    "note_4": "Adjust color scheme to match institutional branding if needed",
    "note_5": "For investor version, emphasize ROI and market size"
  }
}

